Characterization of the Pheochromocytoma-Predominant Subgroup of von Hippel-Lindau Disease

嗜铬细胞瘤为主型冯·希佩尔-林道病亚组的特征分析

阅读:1

Abstract

OBJECTIVE: To define a classification schema for von Hippel-Lindau (VHL) patients who have a pheochromocytoma predominant phenotyope. MATERIALS AND METHODS: VHL patients who underwent adrenalectomy with pathology-proven pheochromocytoma at our institution were included. We defined pheochromocytoma-predominant VHL a priori as patients with one or more of the following traits: early onset [age at first pheochromocytoma below the cohort's median age (28.2years)], family history of pheochromocytomas, multiple pheochromocytomas, and paraganglioma(s). Patients with pheochromocytoma-predominant disease were compared to the remaining cohort to determine differences in genotype and phenotype. RESULTS: One-hundred thirty-nine VHL patients were examined. Preliminary analysis showed that three characteristics (early onset, family history, and multiple pheochromocytomas) were associated. Having paraganglioma(s) did not correlate with the other factors, so it was excluded from the definition of pheochromocytoma-predominant disease. The majority of our patients (110/139, 79%) met the final definition. Pheochromocytoma-predominant patients were less likely to have most additional VHL tumor types, including renal cell carcinoma (P<.001) whereas they were more likely to have missense mutations (P<.001) than the remaining cohort. Overall, pheochromocytoma-predominant patients were most likely to have 0 (P<.001) or 1 (P=.008) extra-adrenal tumor types while non-pheochromocytoma-predominant patients were most likely to have 4 (P=.02) or 5 (P=.02). CONCLUSION: Pheochromocytoma-predominant VHL patients are phenotypically distinct from their non-pheochromocytoma-predominant counterparts and are significantly less likely to have more than one other VHL manifestation, including renal carcinoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。